PCRX
Pacira BioSciences, Inc.
NASDAQ: PCRX · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$22.74
-1.77% today
Updated 2026-05-11
Market cap
$910.90M
P/E ratio
178.08
P/S ratio
1.24x
EPS (TTM)
$0.13
Dividend yield
—
52W range
$19 – $28
Volume
0.7M
Pacira BioSciences, Inc. (PCRX) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
-41.3%
Last 4 quarters
Revenue YoY growth
+5.0%
Most recent quarter
EPS YoY growth
-3.2%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-0.7%
Last 4 reports
Positive reaction rate
50%
2 of 4 quarters
Largest single-day move
-2.4%
2025-08-05
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-05-07 | $0.60 | -20.7% | $23.69 | $23.15 | -2.3% |
| 2026-02-19 | $0.57 | -36.8% | $23.02 | $23.22 | +0.9% |
| 2025-11-06 | $0.70 | +7.7% | $21.85 | $22.05 | +0.9% |
| 2025-08-05 | $-0.11 | -115.3% | $22.94 | $22.40 | -2.4% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2026-03-31 | $0.76 | $0.60 | -20.7% | $177.38M | +5.0% |
| 2025-12-31 | $0.90 | $0.57 | -36.8% | $196.87M | +5.1% |
| 2025-09-30 | $0.65 | $0.70 | +7.7% | $179.52M | +6.5% |
| 2025-06-30 | $0.72 | $-0.11 | -115.3% | $181.10M | +1.7% |
| 2025-03-31 | $0.60 | $0.62 | +3.8% | $168.92M | +1.1% |
| 2024-12-31 | $0.83 | $0.91 | +9.6% | $187.25M | +3.3% |
| 2024-09-30 | $0.70 | $0.79 | +12.9% | $168.57M | +2.8% |
| 2024-06-30 | $0.70 | $0.89 | +27.1% | $178.02M | — |
| 2024-03-31 | $0.62 | $0.62 | +0.0% | $167.12M | — |
| 2023-12-31 | $0.88 | $0.89 | +1.1% | $181.24M | — |
| 2023-09-30 | $0.78 | $0.72 | -7.7% | $163.93M | — |
Frequently asked questions
Has Pacira BioSciences, Inc. beaten earnings estimates?
Pacira BioSciences, Inc. has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of -41.3% over the last 4 quarters.
How does PCRX stock react to earnings?
PCRX stock has moved an average of -0.7% in the trading day following earnings over its last 4 reports, with positive reactions in 50% of those quarters.
What is Pacira BioSciences, Inc.'s revenue growth rate?
Pacira BioSciences, Inc. reported year-over-year revenue growth of +5.0% in its most recent quarter, with EPS growing -3.2% year-over-year.